Cargando…
Tumour treating fields in a combinational therapeutic approach
The standard of care for patients with newly diagnosed Glioblastoma multiforme (GBM) has remained unchanged since 2005, with patients undergoing maximal surgical resection, followed by radiotherapy plus concomitant and maintenance Temozolomide. More recently, Tumour treating fields (TTFields) therap...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290966/ https://www.ncbi.nlm.nih.gov/pubmed/30564303 http://dx.doi.org/10.18632/oncotarget.26344 |
_version_ | 1783380179976978432 |
---|---|
author | Branter, Joshua Basu, Surajit Smith, Stuart |
author_facet | Branter, Joshua Basu, Surajit Smith, Stuart |
author_sort | Branter, Joshua |
collection | PubMed |
description | The standard of care for patients with newly diagnosed Glioblastoma multiforme (GBM) has remained unchanged since 2005, with patients undergoing maximal surgical resection, followed by radiotherapy plus concomitant and maintenance Temozolomide. More recently, Tumour treating fields (TTFields) therapy has become FDA approved for adult recurrent and adult newly-diagnosed GBM following the EF-11 and EF-14 trials, respectively. TTFields is a non-invasive anticancer treatment which utilizes medium frequency alternating electric fields to target actively dividing cancerous cells. TTFields selectively targets cells within mitosis through interacting with key mitotic proteins to cause mitotic arrest and cell death. TTFields therapy presents itself as a candidate for the combinational therapy route due to the lack of overlapping toxicities associated with electric fields. Here we review current literature pertaining to TTFields in combination with alkylating agents, radiation, anti-angiogenics, mitotic inhibitors, immunotherapies, and also with novel agents. This review highlights the observed synergistic and additive effects of combining TTFields with various other therapies, as well highlighting the strategies relating to combinations with electric fields. |
format | Online Article Text |
id | pubmed-6290966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-62909662018-12-18 Tumour treating fields in a combinational therapeutic approach Branter, Joshua Basu, Surajit Smith, Stuart Oncotarget Review The standard of care for patients with newly diagnosed Glioblastoma multiforme (GBM) has remained unchanged since 2005, with patients undergoing maximal surgical resection, followed by radiotherapy plus concomitant and maintenance Temozolomide. More recently, Tumour treating fields (TTFields) therapy has become FDA approved for adult recurrent and adult newly-diagnosed GBM following the EF-11 and EF-14 trials, respectively. TTFields is a non-invasive anticancer treatment which utilizes medium frequency alternating electric fields to target actively dividing cancerous cells. TTFields selectively targets cells within mitosis through interacting with key mitotic proteins to cause mitotic arrest and cell death. TTFields therapy presents itself as a candidate for the combinational therapy route due to the lack of overlapping toxicities associated with electric fields. Here we review current literature pertaining to TTFields in combination with alkylating agents, radiation, anti-angiogenics, mitotic inhibitors, immunotherapies, and also with novel agents. This review highlights the observed synergistic and additive effects of combining TTFields with various other therapies, as well highlighting the strategies relating to combinations with electric fields. Impact Journals LLC 2018-11-27 /pmc/articles/PMC6290966/ /pubmed/30564303 http://dx.doi.org/10.18632/oncotarget.26344 Text en Copyright: © 2018 Branter et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Branter, Joshua Basu, Surajit Smith, Stuart Tumour treating fields in a combinational therapeutic approach |
title | Tumour treating fields in a combinational therapeutic approach |
title_full | Tumour treating fields in a combinational therapeutic approach |
title_fullStr | Tumour treating fields in a combinational therapeutic approach |
title_full_unstemmed | Tumour treating fields in a combinational therapeutic approach |
title_short | Tumour treating fields in a combinational therapeutic approach |
title_sort | tumour treating fields in a combinational therapeutic approach |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290966/ https://www.ncbi.nlm.nih.gov/pubmed/30564303 http://dx.doi.org/10.18632/oncotarget.26344 |
work_keys_str_mv | AT branterjoshua tumourtreatingfieldsinacombinationaltherapeuticapproach AT basusurajit tumourtreatingfieldsinacombinationaltherapeuticapproach AT smithstuart tumourtreatingfieldsinacombinationaltherapeuticapproach |